Melanoma Stage IIIb-IVM1a
1 clinical trials · Condition
◉ Watch Melanoma Stage IIIb-IVM1a
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma (NCT03972046) | TriHealth Inc. | 2019-06-24 |
Track Melanoma Stage IIIb-IVM1a automatically
Every clearance here is in the API, with alerts when new ones post.